Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
Merck Announces First-Quarter 2025 Dividend
Warren Buffett was a net seller of stocks for the eighth consecutive quarter in Q3. Berkshire initiated new positions in only ...
Reuters6h
Merck says Keytruda injection on par with approved IV version in trial
Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday a study showed that its injectable version of cancer drug ...
FiercePharma4h
Taking its best shot at Roche, Merck scores in phase 3 trial of subcutaneous Keytruda
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
STAT3h
Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
Merck announces ‘positive’ results from Phase 3 MK-3475A-D77 trial
Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...
Merck & Co. Raises Quarterly Dividend by 5.2%
Merck & Co.'s board has raised the drugmaker's quarterly dividend by 5.2%, to 81 cents a share from 77 cents. The new payout, equal to $3.24 a year, represents an annual yield of about 3.37%, based on ...
BioSpace3h
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Merck's Phase 3 Study Of Subcutaneous Keytruda To Treat NSCLC Meets Primary Goals
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...